Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-10
2011-10-11
Li, Ruixiang (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
08034771
ABSTRACT:
The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.
REFERENCES:
patent: 4751180 (1988-06-01), Cousens et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5457035 (1995-10-01), Baum et al.
patent: 5599905 (1997-02-01), Mosley et al.
patent: 5877293 (1999-03-01), Adair et al.
patent: 5886152 (1999-03-01), Nakatani et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 6753166 (2004-06-01), Sims et al.
patent: 6838290 (2005-01-01), Sims et al.
patent: 2006/0183161 (2006-08-01), Nicklin et al.
patent: WO 93/10151 (1993-05-01), None
patent: WO 94/10308 (1994-05-01), None
patent: WO 98/42325 (1998-10-01), None
U.S. Appl. No. 09/965,640, filed Sep. 27, 2001, Sims et al.
Altman, et al., “Phenotypic Analysis of Antigen—Specific T Lymphocytes,” Science, 1996, 274:94-96.
Ashkenazi, et al., “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin,” Proc. Natl. Acad. Sci., 1991, 88:10535-10539.
Baron et al., “Co-regulation of two gene activities by tetracycline via a bidirectional promoter,” Nucl. Acids Res., 1995, 23(17):3605-3606.
Baum, et al., “Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand . . . ,” EMBO J., 1994, 13(17):3992-4001.
Blanar, et al., “Interaction Cloning: Identification of a Helix-Loop-Helix Zipper Protein that Interacts with c-Fos,” Science, 1992, 256:1014-1018.
Born, et al., “Cloning of a Novel Receptor Subunit, AcPL, Required for Interleukin-18 Signaling,” J. of Biol. Chem., 1998, 273(45):29445-29450.
Bowie, et al., “A Method to Identify Protein Sequences that Fold into a Known Three-Dimentional Structure,” Science, 1991, 253:164-170.
Byrn, et al., “Biological properties of a CD4 immunoadhesin,” Nature, 1990, 344:667-670.
Chalfie, et al., “Green Fluorescent Protein as a Marker for Gene Expression,” Science, 1994, 263:802-805.
Debets, et al., “Two Novel IL-1 Family Members, IL-67 and IL-68 , Function . . . IL-1 Receptor-Related Protein 2,” J. of Immunology, 2001, 167:1440-1446.
Dunn, et al., “Annotating genes with potential roles in the immune system: six new members of the IL-1 family,” Trends in Immunol., 2001, 22(10):533-536.
Dunn, et al., “High-Resolution Structure of Murine Interleukin 1 Homologue IL-1F5 Reveals Unique Loop Conformations for Receptor Binding . . . ,” Biochem., 2003, 42:10938-10944.
Evans, et al., “Design of Nonpeptidal Ligands for a Peptide Receptor: Cholecystokinin Antagonists,” J. Med. Chem., 1987, 30:1229-1239.
Fanslow, et al., “Structural characteristics of CD40 ligand that determine biological function,” Seminars in Immunology, 1994, 6:267-278.
Fauchere, Jean-Luc, “Elements for the Rational Design of Peptide Drugs,” Advances in Drug Research, 1986, 15:29-69.
Fiscella, et al., “TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model,” Nature Biotech., 2003, 21:302-307.
Gluzman, Y., “SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants,” Cell, 1981 23:175-182.
Hopp, et al., “A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification,” Bio/Technology, 1988, 6:1204-1210.
Hoppe, H.-J., et al., “A parallel three stranded α-helical bundle at the nucleation site of collagen triple-helix formation,” FEBS Letters, 1994, 344:191-195.
Korndörfer, et al., “Crystallographic Analysis of an ‘Anticalin’ with Tailored Specificity for Fluorescein Reveals . . . ,” Proteins: Struc. Func. and Bioinform., 2003, 53:121-129.
Landschulz, et al., “The Leucine Zipper: a Hypothetical Structure Common to a New Class of DNA Binding Proteins,” Science, 1988, 240:1759-1764.
Lunde, et al., “Troybodies and Pepbodies”, Biochemical Society Transations, 2002, 30:500-506.
Maniatis, et al., “Regulation of Inducible and Tissue-Specific Gene Expression,” Science, 1987, 236:1237-1245.
McMahan, et al., “A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types,” EMBO J., 1991, 10(10):2821-2832.
Morrison, S.L., “Transfectomas Provide Novel Chimeric Antibodies,” Science, 1985, 229: 1202-1207.
Paul, W.E., ed. Fundamental Immunology, 2nd Ed., Chapter 7, Du Pasquier, L., “Evolution of the Immune System,” (Raven Press Ltd., New York, 1989), 139-165.
Rasmussen, et al., “Isolation, characterization and recombinant protein expression in Veggie-CHO: A serum-free CHO host cell line,” Cytotechnology, 1998, 28:31-42.
Rizo, et al., “Contrained Peptides: Models of Bioactive Peptides and Protein Substructures,” Annu. Rev. Biochem., 1992, 61:387-418.
Roque, et al., “Antibodies and Genetically Engineered Related Molecules: Production and Purification,” Biotechnol. Prog., 2004, 20:639-654.
Schier, et al., “Isolation of Picomolar Affinity Anti-cerbB-2 Single-chain Fv by Molecular Evolution . . . ,” J. Mol. Biol., 1996, 263:551-567.
Schmitz, et al., “IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 & Induces T Helper Type 2-Assoc . . . ,” Immunity, 2005, 23:479-490.
Sims, et al., “A new nomenclature for IL-1-family genes,” Trends in Immunology, 2001, 22(10):536-537.
Smith, et al., “Single-step purification of polypeptides expressed inEscherichia colias fusions with glutathione S-transferase,” Gene, 1988, 67:31-40.
Thornton, et al., “Prediction of progress at last,” Nature, 1991, 354:105-106.
Towne, et al., “Interleukin (IL)-1F6, IL-1F8, and IL-1F9 Signal through IL-1Rrp2 and IL-1RAcP to Activate the Pathway . . . ,” J. Biol. Chem., 2004, 279(14):13677-13688.
Urlaub, et al., “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,” Proc. Natl. Acad. Sci., 1980, 77(7):4216-4220.
Verber, et al., “The design of metabolically-stable peptide analogs,” Trends in Neurosciences, Sep. 1985, pp. 392-396.
Voss, et al., “The role of enhancers in the regulation of cell-type-specific transcriptional control,” Trends Biochem. Sci. Jul. 11, 1986, 287-289.
Hollenbaugh, et al., “Construction of Immunoglobulin Fusion Proteins,” Current Protocols in Immunology, 1992, Suppl. 4, pp. 10.19.1-10.19.11.
Humke, et al., “ICEBERG: A Novel Inhibitor of Interleukin-1β Generation,” Cell, 2000, 103:99-111.
Kumar, Sanjay, “Identification and Initial Characterization of Four Novel Members of the Interleukin-1 Family,” J. Biol. Chem., 2000, 275(14):10308-10314.
Ng, et al., “Differential effects of interleukin-1β and transforming growth factor β1 on the expression of . . . ADAMTS-1 . . . ,” Human Reproduction, 2006, 21(8):1990-1999.
Nicklin, et al., “A Sequence-Based Map of the Nine Genes of the Human Interleukin-1 Cluster,” Genomics, 2002, 79(5):718-725.
Renshaw, et al., “Processing of IL-1 Family Members is Key to their Activity,” Inflammation Research, 2007, 56(Suppl. 3):S430.
Smith, et al., “Four New Members Expand the Interleukin-1 Superfamily,” J Biol. Chem., 2000, 275(2):1169-1175.
Gabel Christopher
Ketchem Randal R.
Renshaw Blair R.
Sims John E.
Towne Jennifer E.
Amgen Inc.
Hehman Mary K.
Li Ruixiang
LandOfFree
IL-1F6 polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL-1F6 polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-1F6 polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298187